We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Prevention is better than cure — but is too costly for some countries where drug-resistant bacteria are rampant
Identifying conditions can prevent inappropriate drug use, but there are barriers to progress in poorer regions
Global co-operation is desperately needed to overcome threat from drug-resistant infections
Broader funding, registration and stewardship is pivotal to making the antibiotic market more sustainable
Study finds lower middle income countries in South Asia and Latin America have highest levels of pollutants
Move could boost global development of drugs to ease antimicrobial resistance
Fixed fee aims to incentivise pharma groups to develop new drugs and curb overprescription
Drug-resistant pathogens and poor hygiene mean simple procedures can deteriorate into lengthy and costly infections
New drugs are needed as resistance grows but plans to improve incentives are too modest, executives say
To save lives and economies, we must make progress by drawing on lessons from Covid-19
Research underscores the dangers of bacteria developing the ability to resist drugs
FT dashboard tracks responses to the growing threat of antimicrobial resistance
Political will is needed to address absence of sufficient financial incentives for new drugs
Failure to ensure they reach world’s poorest increases health risks, says pharma body
The pandemic highlighted weaknesses in global health systems but has spurred a powerful response. Plus: how climate change risks backsliding on gains against malaria; long Covid perplexes researchers; new HIV treatments in the pipeline; why the fight against antimicrobial resistance is making slow progress
Without decisive action, there could be 10m deaths a year due to AMR by 2050 — and a cumulative cost to the global economy of $100tn
Israeli start-up MeMed aims to cut unnecessary prescribing of antibiotics with 15-minute procedure
Medics turning unnecessarily to antibacterials during first wave triggers concern over accelerated resistance
Global health body warns none of antibiotics currently being developed are enough to tackle superbugs
The current pandemic has shown the value of planning ahead of crises
Recommendations from two FT roundtables with pharma, government, and NGO experts
New models are emerging to allow pharma companies to turn a profit regardless of how much new antibiotics are used
A South African doctor’s prescription to stop poorer countries losing access to many of modern medicine’s advances
Household names like McDonald’s start to modify practices to aid farm animals’ health, growth and digestion
Chemicals company makes largest donation for science in university’s history
International Edition
